Cargando…

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors

BACKGROUND: Omaveloxolone is a semisynthetic oleanane triterpenoid that potently activates Nrf2 with subsequent antioxidant function. We conducted a first-in-human Phase I clinical trial (NCT02029729) with the primary objectives to determine the appropriate dose for Phase II studies, characterize ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Creelan, Ben C, Gabrilovich, Dmitry I, Gray, Jhanelle E, Williams, Charles C, Tanvetyanon, Tawee, Haura, Eric B, Weber, Jeffrey S, Gibney, Geoffrey T, Markowitz, Joseph, Proksch, Joel W, Reisman, Scott A, McKee, Mark D, Chin, Melanie P, Meyer, Colin J, Antonia, Scott J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587199/ https://www.ncbi.nlm.nih.gov/pubmed/28919776 http://dx.doi.org/10.2147/OTT.S136992

Ejemplares similares

Variable effects of omaveloxolone (RTA408) on primary fibroblasts with mitochondrial defects
por: Zighan, Madleen, et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates
por: Reisman, Scott A, et al.
Publicado: (2019)

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer
por: Chiappori, Alberto A., et al.
Publicado: (2018)

RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity
por: Probst, Brandon L., et al.
Publicado: (2015)

Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteers
por: Reisman, Scott A., et al.
Publicado: (2015)

Omaveloxolone and TX63682 are hepatoprotective in the STAM mouse model of nonalcoholic steatohepatitis
por: Reisman, Scott A., et al.
Publicado: (2020)

Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
por: Creelan, Ben C., et al.
Publicado: (2019)

A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma
por: Gray, Jhanelle E., et al.
Publicado: (2018)

A unique tolerizing dendritic cell phenotype induced by the synthetic triterpenoid CDDO-DFPA (RTA-408) is protective against EAE
por: Wei, Hsi-Ju, et al.
Publicado: (2017)

Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia
por: Lynch, David R., et al.
Publicado: (2018)

Impact of COVID-19 Pandemic on Frontline Pembrolizumab-Based Treatment for Advanced Lung Cancer
por: Tanvetyanon, Tawee, et al.
Publicado: (2023)

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease()
por: Aminzadeh, Mohammad A., et al.
Publicado: (2013)

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease
por: Aminzadeh, Mohammad A., et al.
Publicado: (2014)

The Nrf2 activator RTA-408 attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling
por: Sun, Xuewu, et al.
Publicado: (2019)

The novel triterpenoid RTA 408 protects human retinal pigment epithelial cells against H(2)O(2)-induced cell injury via NF-E2-related factor 2 (Nrf2) activation
por: Liu, Xiaobin, et al.
Publicado: (2015)

Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study)
por: Lynch, David R., et al.
Publicado: (2020)

RTA-408 Protects Kidney from Ischemia-Reperfusion Injury in Mice via Activating Nrf2 and Downstream GSH Biosynthesis Gene
por: Han, Peng, et al.
Publicado: (2017)

Mechanisms and therapeutic implications of RTA 408, an activator of Nrf2, in subarachnoid hemorrhage–induced delayed cerebral vasospasm and secondary brain injury
por: Tsai, Tai-Hsin, et al.
Publicado: (2020)

Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone
por: Ghanekar, Shaila D, et al.
Publicado: (2019)

A Bayesian pick-the-winner design in a randomized phase II clinical trial
por: Chen, Dung-Tsa, et al.
Publicado: (2017)

Emerging Approaches to Complement Low-Dose Computerized Tomography for Lung Cancer Screening: A Narrative Review
por: Maller, Bradley, et al.
Publicado: (2022)

Amivantamab for Metastatic Lung Cancer With Paraneoplastic Disseminated Intravascular Coagulation: A Case Report
por: Ahmad, Yaser, et al.
Publicado: (2023)

Fatal Tracheoesophageal Puncture Leakage Associated With Lenvatinib
por: Salvatori, Sarah, et al.
Publicado: (2023)

Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299
por: Dudek, Arkadiusz Z., et al.
Publicado: (2023)

The synthetic triterpenoid, RTA405, increases glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells
por: Ding, Yanfeng, et al.
Publicado: (2012)

Prognostic Value of Positron Emission Tomography in Advanced Cholangiocarcinoma: A Single-Institution Study and Literature Review
por: Pevner, Justin L, et al.
Publicado: (2022)

Iatrogenic Rupture of Saline Breast Implant Following Robotic-Assisted Lung Surgery
por: Cui, Joyce Y, et al.
Publicado: (2023)

RTA‐408 protects against propofol‐induced cognitive impairment in neonatal mice via the activation of Nrf2 and the inhibition of NF‐κB p65 nuclear translocation
por: Zhang, Ling, et al.
Publicado: (2020)

RTA 408 Inhibits Interleukin-1β-Induced MMP-9 Expression via Suppressing Protein Kinase-Dependent NF-κB and AP-1 Activation in Rat Brain Astrocytes
por: Yang, Chien-Chung, et al.
Publicado: (2019)

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function
por: Shoaf, Susan E, et al.
Publicado: (2014)

Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer
por: Souwer, E. T. D., et al.
Publicado: (2023)

Impact of Robotic-Assisted Thoracic Surgery on the Completion of Adjuvant Chemotherapy Following Lung Cancer Resection
por: Abdelghany, Khaled, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
por: Härtter, Sebastian, et al.
Publicado: (2012)

Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects
por: Moore, Kenneth Todd, et al.
Publicado: (2015)

The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus
por: Dudkowski, Caroline, et al.
Publicado: (2016)

Initial Commissioning Results of the RTA Injector
por: Eylon, S, et al.
Publicado: (1999)

At R407/R408
Publicado: (1974)

Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease
por: Hassanpour, Rezvan, et al.
Publicado: (2021)

Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
por: Lee, Sun Ku, et al.
Publicado: (2017)

Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405
por: Probst, Brandon L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_m3jafcp7oe14n82ausm8b45md9